Development and validation of a liquid chromatography-tandem mass spectrometry method to determine ulifloxacin, the active metabolite of prulifloxacin in rat and rabbit plasma: Application to toxicokinetic study

Biomedical Chromatography

Volumn 25, Issue 8, 2011, Pages 890-901

  Roy, Bikash ^a   Choudhury, Hira ^a   Das, Ayan ^a   Das, Anjan Kumar ^a   Pal, Tapan Kumar ^a  

^a JADAVPUR UNIVERSITY   (India)

Author keywords

Liquid chromatography tandem mass spectrometry; Prulifloxacin; Toxicokinetics; Ulifloxacin; Validation

Indexed keywords

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH PRESSURE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY;

ACTIVE METABOLITES; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY; PRULIFLOXACIN; RABBIT PLASMAS; RAT PLASMA; SIMPLE++; TOXICOKINETICS; ULIFLOXACIN; VALIDATION;

RATS;

CIPROFLOXACIN; FORMIC ACID; METHANOL; PRULIFLOXACIN; ULIFLOXACIN; WATER;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; EXPERIMENTAL RABBIT; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIMIT OF DETECTION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICOKINETICS;

ORYCTOLAGUS CUNICULUS; RATTUS;

EID: 79960025401     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1539     Document Type: Article

References (19)

1. Center for Drug Evaluation and Research, and Center for Biologics Evaluation and Research. Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers. US Food and Drug Administration, Rockville, MD, 2002. USA.
2. Fen YF, Li KX, Xie F and Sun CH, Determination of the active metabolite of prulifloxacin in human plasma by HPLC with fluorescence detection. Chinese Journal of Pharmaceutical Analysis 2006; 26: 755-758.
3. Food and Drug Administration of the United States. Guidance for Industry-Bioanalytical Method Validation. US Department of Health and Human Services, Center for Drug Evaluation and Research and Center for Veterinary Medicine, 2001. Available from.
4. Giannarini G, Tascini C and Selli C. Prulifloxacin: clinical studies of a broad-spectrum quinolone agent. Future Microbiology 2009; 4(1): 13-24.
5. Guo L, Qi M, Jin X, Wang P and Zhao H. Determination of the active metabolite of prulifloxacin in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences 2006; 832(2): 280-285.
6. Jun W, Zhenyu Z, Zhanying H, Yiwen W, Yan F, Mei L, Guorong F and Yutian W. Determination of the active metabolite of prulifloxacin in human plasma by HPLC with fluorescence detection. Chromatographia 2007; 66: 37-41.
7. Keam SJ and Perry CM. Prulifloxacin. Drugs 2004; 64: 2221-2234.
8. Matera MG, Pharmacologic characteristics of prulifloxacin. Pulmonary Pharmacology and Therapeutics 2006; 19: 20-29.
9. Nakashima M, Uematsu T, Kosuge K, Okuyama Y, Morino A, Ozaki M and Takebe Y. Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers. Journal of Clinical Pharmacology 1994; 34: 930-937.
10. Pico Y and Andreu V. Fluoroquinolones in soil-risks and challenges. Analytical and Bioanalytical Chemistry 2007; 387: 1287-1299.
11. Picollo R, Brion N, Gualano V, Millerioux L, Marchetti M, Rosignoli MT and Dionisio P. Pharmacokinetics and tolerability of prulifloxacin after single oral administration Arzneimittel-Forschung 2003; 53: 201-205.
12. Prats G, Rossi V, Salvatori E and Mirelis B. Prulifloxacin: a new antibacterial fluoroquinolone. Expert Review of Anti-infective Therapy 2006; 4: 27-41.
13. Roy B, Das A, Bhaumik U, Sarkar AK, Bose A, Mukharjee J, Chakrabarty US, Das AK and Pal TK. Determination of gemifloxacin in different tissues of rat after oral dosing of gemifloxacin mesylate by LC-MS/MS and its application in drug tissue distribution study Journal of Pharmaceutical and Biomedical Analysis 2010; 52: 216-226.
14. Shaw SR, Nihal M and Ahmad N. Dose translation from animal to human studies revisited. FASEB Journal 2008; 22: 659-661.
15. Stamatia LK. Determination of aminoglycosides and quinolones in food using tandem mass spectrometry: a review. Critical Reviews in Food Science and Nutrition, 2004; 44:173-184.
16. Thomas RF, Douglas JB and Ronald NJ. Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea. Antimicrobial Agents Chemotherapy 2009; 53(3): 1221-1224.
17. Tougou K, Nakamura A, Watanabe S, Okuyama Y and Morino A. Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent. Drug Metabolism and Disposition 1998; 26: 355-359.
18. Wang X, Shen B, Zhao H and Jin L. Determination of ulifloxacin by terbium-sensitized fluorescence with second-order scattering and its applications. Analytical Sciences 2007; 23: 1373-1376.
19. Zhang L, Wen J, Pan Y, Li Z, Fan G and Wu Y. Determination of ulifloxacin, the active metabolite ofprulifloxacin, in human plasma by a 96-well format solid-phase extraction and capillary zone electrophoresis. Journal of Chromatography, B 2008; 872: 172-176.